Childhood Cancer

Dr. Danewa recommended Nathan and Oski's Hematology and Oncology of Infancy and Childhood as the primary reference, alongside Lanzkowsky's Manual of Pediatric Hematology and Oncology, and offered to share his own treatment protocols and presentations directly with any doctor who requests them.

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

Dr. Danewa explained that upfront bone marrow transplant has no role in most pediatric leukemia. It is reserved for cases without morphological remission (blasts above 10% at the end of induction), for hypodiploidy (fewer than 44 chromosomes), or for relapse. For benign conditions, the leading indication, especially in Africa, is sickle cell disease, where earlier transplant, ideally before age 12 and before pain crises, stroke or chest syndrome accumulate, gives a better outcome. He described three transplant types: matched sibling, matched unrelated donor via registry, and haploidentical transplant from a parent, with haploidentical success running around 70 to 80% depending on the underlying disease.

Yes. Dr. Danewa confirmed bone marrow transplant is a cure for sickle cell disease, and that outcomes are best the earlier it is done, since delay allows organ damage and comorbidities to accumulate and lowers the chance of success.

Pediatric cancer differs from adult cancer in three ways: the biology of the disease itself, the dosing and treatment protocols, and the goal of treatment. Adult oncology sometimes weighs treatment against quality of life, while pediatric oncology aims for lifelong survival with a normal, healthy adulthood, since a child has decades of life ahead.

In a general oncology outpatient department of 100 patients, only 15 to 20 are children. Among them, leukemia accounts for roughly 30 to 40%, followed by brain tumors, then lymphomas. Neuroblastoma and Wilms tumor dominate abdominal cases, osteosarcoma and Ewing sarcoma dominate bone cases, and retinoblastoma is the most common childhood eye cancer.

Survival stood at 20 to 30% in 1948 and runs at 80 to 90% today, achieved largely with the same core chemotherapy drugs used since 1970. The improvement came from better diagnostics and risk stratification rather than new medicines.

No. Cancers that define adult oncology practice, including lung cancer, prostate cancer and multiple myeloma, essentially do not appear in children at all.

Pediatric brain tumors carry 70 to 80% overall survival. Even stage 4 Wilms tumor, a stage that signals a very different prognosis in most adult cancers, still carries 60 to 70% survival in children.